arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Enovis CORP

ENOV
$26.62 ▲ +0.29 (+1.08%) at close
Healthcare ·Orthopedic, Prosthetic & Surgical Appliances & Supplies ·USOrthopedic, Prosthetic & Surgical Appliances & Supplies
63 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Enovis CORP faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.5B
Dividend Yield
Revenue Growth 5.4%
Op. Margin 1.1%
ROIC -3.1%
FCF / Share $-0.50
Trailing P/E
Price / Book 1.0x
FCF Yield
Debt / Equity 0.90
info Valuation on last close. End-of-day price, Aug 7, 2026.

63-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$589.15M
↑ +5.4%
Net Income Profit after all expenses
$-8.76M
↑ +84.3%
Operating Margin Operating profit as % of sales
1.1%
↑ +101.3% 5th
FCF / Share Free cash flow per share
$-0.50
↑ +36.3%
Long-Term Debt Long-term obligations
$1.33B
↑ +2.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
13
Returns
11
Financial Health
27
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 63 quarters